发明名称 |
T-CELL REDIRECTING BISPECIFIC ANTIBODIES FOR TREATMENT OF DISEASE |
摘要 |
The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3 x anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The the cytotoxic immune response is enhanced by co-administration of interfon-based agents that comprise interferon-a, interferon-ß, interferon-?1, interferon-?2 or interferon-?3. |
申请公布号 |
CA2874864(A1) |
申请公布日期 |
2014.02.20 |
申请号 |
CA20132874864 |
申请日期 |
2013.08.14 |
申请人 |
IBC PHARMACEUTICALS, INC. |
发明人 |
CHANG, CHIEN-HSING;GOLDENBERG, DAVID M.;ROSSI, EDMUND A.;ROSSI, DIANE |
分类号 |
C07K16/18;A61K38/19;A61K38/21;A61K39/395;A61K45/06;A61K47/42;C07K16/28;C07K16/32;C07K16/40 |
主分类号 |
C07K16/18 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|